BioSpace News Archive

Transparency Market Research has published a new report on the global collagen and HA-based biomaterials market for the forecast period of 2019–2027.

Transparency Market Research has published a new report titled, “Canes and Crutches Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”.

Pure, homogenous and stable chemicals, analytical standards are responsible for precision in quantitative analysis and thus, they are used in examination of analytical method performance and calibration of apparatus.

Since they are scrutinized thoroughly before approvals and monitored in a highly controlled manner, owing to their sheer implications as they are implanted into the body – the market for active implantable medical devices has always been confined within a few players who have the technological expertise to abide by the stringent regulations.

Midatech Pharma PLC announces that it has issued to certain US investors 500,000 American Depositary Shares, representing 2,500,000 ordinary shares of 0.1p each in the Company, in connection with the exercise of pre-existing warrants by such investors at an exercise price of $2.05 per ADS.

Lead Asset Nipocalimab Provides Opportunity for Janssen to Deliver Transformative Treatments in Autoantibody-Driven Autoimmune Diseases

KEYTRUDA Is First Anti-PD-1 Therapy in Combination With Chemotherapy to Show Superior Survival Benefit as First-Line Treatment for Patients With Esophageal Cancer Regardless of Histology

Lannett Company, Inc. announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes.

Turning Point Therapeutics, Inc., a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported early interim data from the registrational Phase 2 TRIDENT-1 study of lead drug candidate, repotrectinib, and announced recent regulatory feedback from the Food and Drug Administration on the TRIDENT-1 trial design.

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments including ag-biologicals, ag-chemicals, human microbiome based therapies and medical cannabis, announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 9:40 AM ET.